SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS).
Gene editing
FDA Eyes Accelerated Reviews for Gene Editing Therapies
Vinay Prasad, chief of the FDA’s Center for Biologics Evaluation and Research, is planning to publish a paper this month to outline his office’s thinking on accelerating gene editing reviews.
November 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Sponsored
Viral Vector Manufacturing: Case Studies and Considerations from a CDMO Perspective
Optimization Through Culture, Quality Control and Regulatory Standards
November 3, 2025
 · 
14 min read
Two businessman taking competition.Overtaking
Editorial
Novo’s CEO Doesn’t Seem To Mind Being Big Pharma’s Villian
Novo Nordisk, under new CEO Maziar Mike Doustdar, has a new attitude. It’s making Pfizer livid.
October 31, 2025
 · 
3 min read
 · 
Annalee Armstrong
South San Francisco, CA, USA - Feb 23, 2024: Exterior view of AbbVie's research facility in South San Francisco. AbbVie is an American pharmaceutical company headquartered in North Chicago, Illinois.
Earnings
AbbVie’s Immunology Dyad Dominates Again in Q3
Skyrizi and Rinvoq made nearly $7 billion combined, almost half of the company’s income for the quarter alone.
October 31, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Futuristic Cyber Abstracy Eye Background 4K
Deals
4DMT Sends Eye Disease Asset’s Asia Rights to Otsuka for $85M Upfront
Otsuka Pharmaceuticals could shell out over $400 million in total for the Asia-Pacific rights to 4D-150, which combines a VEGF-C inhibitory RNAi with Regeneron’s Eylea into a single ocular injection.
October 31, 2025
 · 
1 min read
 · 
Annalee Armstrong
Eli Lilly's biotechnology center in California
Pain
Lilly Refines Pain Pipeline Again, Scrapping Mid-Stage Program
Before being discontinued, the P2X7 receptor blocker had cleared a master protocol study in chronic pain, though Eli Lilly said that results were not sufficient for advancement of the Asahi Kasei–partnered asset.
October 31, 2025
 · 
2 min read
 · 
Tristan Manalac
Contemporary digital collage art. Modern trippy design. Hands holding fork and spoon
Earnings
Gilead Still Hungry for Deals as HIV Portfolio Grows, Veklury Crashes
Gilead is actively looking for late-stage and de-risked assets for potential deals across various therapeutic spaces, including liver disease, cancer and immunology.
October 31, 2025
 · 
2 min read
 · 
Tristan Manalac
Concept art showing a money icon and human hands
IPO
Evommune Joins IPO Class With Planned $160M Raise for Immuno Pipeline
With the shutdown ongoing, Evommune plans to close its IPO on Nov. 5 via a Securities Act clause that allows registrations to come into effect after a certain window has passed.
October 31, 2025
 · 
2 min read
 · 
Tristan Manalac
Ladder of Success
C-suite
An Early-Career Stand Proved This Young Biotech Exec Had What It Takes
Ensho Therapeutics CEO Neena Bitritto-Garg, recently named to BioSpace’s 40 Under 40, proved her mettle managing one of the toughest partnerships out there: the one between Eisai and Biogen that led to new Alzheimer’s drugs Aduhelm and Leqembi.
October 31, 2025
 · 
6 min read
 · 
Annalee Armstrong
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS